120 related articles for article (PubMed ID: 15800951)
1. Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy.
Barczyk K; Kreuter M; Pryjma J; Booy EP; Maddika S; Ghavami S; Berdel WE; Roth J; Los M
Int J Cancer; 2005 Aug; 116(2):167-73. PubMed ID: 15800951
[TBL] [Abstract][Full Text] [Related]
2. Extracellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of non-small cell lung cancer patients.
Javid J; Mir R; Julka PK; Ray PC; Saxena A
Tumour Biol; 2015 Jun; 36(6):4253-60. PubMed ID: 25578497
[TBL] [Abstract][Full Text] [Related]
3. Serum cytochrome c to indicate the extent of ongoing tumor cell death.
Osaka A; Hasegawa H; Tsuruda K; Inokuchi N; Yanagihara K; Yamada Y; Aoyama M; Sawada T; Kamihira S
Int J Lab Hematol; 2009 Jun; 31(3):307-14. PubMed ID: 18279425
[TBL] [Abstract][Full Text] [Related]
4. Prognostic predictive values of serum cytochrome c, cytokines, and other laboratory measurements in acute encephalopathy with multiple organ failure.
Hosoya M; Kawasaki Y; Katayose M; Sakuma H; Watanabe M; Igarashi E; Aoyama M; Nunoi H; Suzuki H
Arch Dis Child; 2006 Jun; 91(6):469-72. PubMed ID: 16443616
[TBL] [Abstract][Full Text] [Related]
5. Serum leucine-rich alpha-2-glycoprotein-1 binds cytochrome c and inhibits antibody detection of this apoptotic marker in enzyme-linked immunosorbent assay.
Cummings C; Walder J; Treeful A; Jemmerson R
Apoptosis; 2006 Jul; 11(7):1121-9. PubMed ID: 16699948
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of soluble Fas ligand, granzyme B and cytochrome c during adjuvant chemotherapy of breast cancer.
Kadam CY; Abhang SA
Clin Chim Acta; 2015 Jan; 438():98-102. PubMed ID: 25139496
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis Markers in Breast Cancer Therapy.
Kadam CY; Abhang SA
Adv Clin Chem; 2016; 74():143-93. PubMed ID: 27117663
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
Szarvas T; Becker M; Vom Dorp F; Meschede J; Scherag A; Bánkfalvi A; Reis H; Schmid KW; Romics I; Rübben H; Ergün S
Int J Cancer; 2011 Mar; 128(6):1486-92. PubMed ID: 20473942
[TBL] [Abstract][Full Text] [Related]
9. The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients.
Barak V; Meirovitz A; Leibovici V; Rachmut J; Peretz T; Eliashar R; Gross M
Anticancer Res; 2015 Oct; 35(10):5519-24. PubMed ID: 26408719
[TBL] [Abstract][Full Text] [Related]
10. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
11. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients.
Degen M; Brellier F; Schenk S; Driscoll R; Zaman K; Stupp R; Tornillo L; Terracciano L; Chiquet-Ehrismann R; Rüegg C; Seelentag W
Int J Cancer; 2008 Jun; 122(11):2454-61. PubMed ID: 18306355
[TBL] [Abstract][Full Text] [Related]
12. Detection of cytochrome C in a single cell using an optical nanobiosensor.
Song JM; Kasili PM; Griffin GD; Vo-Dinh T
Anal Chem; 2004 May; 76(9):2591-4. PubMed ID: 15117202
[TBL] [Abstract][Full Text] [Related]
13. Serum cytochrome c level as a prognostic indicator in patients with systemic inflammatory response syndrome.
Adachi N; Hirota M; Hamaguchi M; Okamoto K; Watanabe K; Endo F
Clin Chim Acta; 2004 Apr; 342(1-2):127-36. PubMed ID: 15026273
[TBL] [Abstract][Full Text] [Related]
14. Glutamate-induced apoptosis in primary cortical neurons is inhibited by equine estrogens via down-regulation of caspase-3 and prevention of mitochondrial cytochrome c release.
Zhang Y; Bhavnani BR
BMC Neurosci; 2005 Feb; 6():13. PubMed ID: 15730564
[TBL] [Abstract][Full Text] [Related]
15. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers.
Kuroda H; Mochizuki S; Shimoda M; Chijiiwa M; Kamiya K; Izumi Y; Watanabe M; Horinouchi H; Kawamura M; Kobayashi K; Okada Y
Int J Cancer; 2010 Oct; 127(8):1844-56. PubMed ID: 20112342
[TBL] [Abstract][Full Text] [Related]
16. Cytochrome c is a possible new marker for fulminant hepatitis in humans.
Sakaida I; Kimura T; Yamasaki T; Fukumoto Y; Watanabe K; Aoyama M; Okita K
J Gastroenterol; 2005 Feb; 40(2):179-85. PubMed ID: 15770402
[TBL] [Abstract][Full Text] [Related]
17. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
Fahmueller YN; Nagel D; Hoffmann RT; Tatsch K; Jakobs T; Stieber P; Holdenrieder S
Int J Cancer; 2013 May; 132(10):2349-58. PubMed ID: 23047645
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.
Wu Y; Han B; Sheng H; Lin M; Moore PA; Zhang J; Wu J
Int J Cancer; 2003 Jul; 105(5):724-32. PubMed ID: 12740925
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome c: potential as a noninvasive biomarker of drug-induced acute kidney injury.
Small DM; Gobe GC
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):655-64. PubMed ID: 22475359
[TBL] [Abstract][Full Text] [Related]
20. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker.
Linder S; Havelka AM; Ueno T; Shoshan MC
Cancer Lett; 2004 Oct; 214(1):1-9. PubMed ID: 15331168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
